Tenax Therapeutics Inc (TENX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $73.77M
Last updated: Nov 17, 2026 at 4:25 PM ET
Tenax Therapeutics Inc (TENX) Statistics
Tenax Therapeutics (TENX) has a market cap of $73.77M. Its share count is up 34.50% from a year earlier. It holds $113.73M more cash than debt, 154.17% of its market cap.
Total Valuation
| Market Cap | $73.77M |
|---|---|
| Latest price (Nov 17, 2026) | $1.42 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 80.00% over 52 weeks and trades 19.77% below its 50-day average.
| Beta (1Y) | 1.32 |
|---|---|
| 52-Week Change | -80.00% |
| 1-Month Change | -6.58% |
| 3-Month Change | -25.26% |
| 6-Month Change | -87.63% |
| 5-Year Change | -99.93% |
| 10-Year Change | -100.00% |
| Total Return (1Y) | -80.00% |
| Total Return (3Y CAGR) | -64.02% |
| Total Return (5Y CAGR) | -76.64% |
| Return vs SPY (1Y) | -93.08% |
| Max Drawdown (1Y) | -92.58% |
| Max Drawdown (3Y) | -95.76% |
| Sharpe Ratio (1Y) | -0.69 |
| Correlation with SPY (1Y) | 0.07 |
| 50-Day Average | $1.77 |
| 200-Day Average | $9.29 |
| 52-Week Range | $1.31 to $19.40 |
| RSI (14 Days) | 33.4 |
| Average Volume (20 Days) | 1.47M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 14.01x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 14.01x |
|---|---|
| Quick Ratio | 14.01x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -60.52% and return on assets is -56.20% over the last 12 months.
| Return on Equity (ROE) | -60.52% |
|---|---|
| Return on Assets (ROA) | -56.20% |
Scores
TENX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue of $0 over the last 12 months is down 100.00% from the 12 months before.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$69.53M |
| Pretax Income | -$65.76M |
| Net Income | -$65.76M |
| Reported EPS (TTM) | -$1.39 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 92.86% of the $117.01M in total assets.
| Cash and Equivalents | $113.73M |
|---|---|
| Total Debt | $0 |
| Net Cash | $113.73M |
| Net Cash Per Share | $2.13 |
| Working Capital | $108.66M |
| Shareholder Equity | $108.66M |
| Book Value Per Share | $2.03 |
| Total Assets | $117.01M |
| Total Liabilities | $8.36M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $0 of capital spending, operating cash flow left -$49.35M of free cash flow.
| Operating Cash Flow | -$49.35M |
|---|---|
| Capital Expenditures | $0 |
| Free Cash Flow | -$49.35M |
| FCF Per Share | -$1.08 |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
TENX does not pay a dividend. Its free cash flow yield is -65.02%.
| FCF Yield | -65.02% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-80 reverse split on Jan 3, 2024.
| Last Split Date | Jan 3, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:80 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TENX
What is TENX's market cap?
Tenax Therapeutics has a market cap of $73.77M.
How many shares of TENX are outstanding?
Tenax Therapeutics has 53.45M shares outstanding. The count is up 34.50% from a year earlier.
Does TENX pay a dividend?
No. Tenax Therapeutics does not pay a dividend.
How much debt does TENX have?
Tenax Therapeutics has $0 of total debt and $113.73M of cash and equivalents, a net cash position of $113.73M.
TENX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors